Protective and pathogenic antibody responses from a primate Shigella outbreak inform vaccine design
There is currently no approved vaccine for Shigella spp., a leading cause of diarrhea that are increasingly resistant to antimicrobials. Shigella vaccine development is complicated in part by an incomplete understanding of the structural and molecular determinants of immunity. To address this, we isolated monoclonal antibodies (mAbs) against candidate Shigella vaccine antigens using samples from a Shigella flexneri outbreak in a non-human primate (NHP) research facility. We found that antibodies targeting the Shigella O-antigen (O-Ag) can undergo significant affinity maturation (>10%) to acquire broad cross-reactivity across S. flexneri serotypes. We also found that the virulence-associated type III secretion system (T3SS) proteins IpaD and IpaB elicit moderate T cell and robust antibody responses. T3SS antibodies either inhibit, or - surprisingly - enhance bacterial virulence in vitro and in vivo depending on their epitope specificity. These findings provide key insights into protective and deleterious immune responses against Shigella that directly inform vaccine immunogen design.